[1]
|
M. Chanrion, V. Negre, H. Fontaine, N. Salvetat, F. Bibeau, G. Mac Grogan, L. Mauriac, D. Katsaros, F. Molina, C. Theillet and J. M. Darbon, “A Gene Expression Signature That Can Predict the Recurrence of Tamoxifen-Treated Primary Breast Cancer,” Clinical Cancer Research, Vol. 14, No. 6, 2008, pp. 1744-1752.
doi:10.1158/1078-0432.CCR-07-1833
|
[2]
|
S. P. Linke, T. M. Bremer, C. D. Herold, G. Sauter and C. Diamond, “A Multimarker Model to Predict Outcome in Tamoxifen-Treated Breast Cancer Patients,” Clinical Cancer Research, Vol. 12, No. 4, 2006, pp. 1175-1183.
doi:10.1158/1078-0432.CCR-05-1562
|
[3]
|
P. E. L?nning, S. Knappskog, V. Staalesen, R. Chrisanthar and J. R. Lillehaug, “Breast Cancer Prognostication and Prediction in the Postgenomic Era,” Annals of Oncology, Vol. 18, No. 8, 2007, pp. 1293-1306.
doi:10.1093/annonc/mdm013
|
[4]
|
M. A. Folgueira, D. M. Carraro, H. Brentani, D. F. Patr?o, E.M. Barbosa, M. M. Netto, J. R. Caldeira, M. L. Katayama, F. A. Soares, C. T. Oliveira, L. F. Reis, J. H. Kaiano, L. P. Camargo, R. Z. Vêncio, I. M. Snitcovsky, F. B. Makdissi, P. J. e Silva, J. C. Góes and M. M. Brentani, “Gene Expression Profile Associated with Response to Doxorubicin-Based Therapy in Breast Cancer,” Clinical Cancer Research, Vol. 11, No. 20, 2005, pp. 7434-7443.
doi:10.1158/1078-0432.CCR-04-0548
|
[5]
|
H. K. Dressman, C. Hans, A. Bild, J. A. Olson, E. Rosen, P. K. Marcom, V. B. Liotcheva, E. L. Jones, Z. Vujaskovic, J. Marks, M. W. Dewhirst, M. West, J. R. Nevins and K. Blackwell, “Gene Expression Profiles of Multiple Breast Cancer Phenotypes and Response to Neoadjuvant Chemotherapy,” Clinical Cancer Research, Vol. 12, No. 3, 2006, pp. 819-826.
doi:10.1158/1078-0432.CCR-05-1447
|
[6]
|
O. Thuerigen, A. Schneeweiss, G. Toedt, P. Warnat, M. Hahn, H. Kramer, B. Brors, C. Rudlowski, A. Benner, F. Schuetz, B. Tews, R. Eils, H.-P. Sinn, C. Sohn and P. Lichter, “Gene Expression Signature Predicting Pathologic Complete Response with Gemcitabine, Epirubicin, and Docetaxel in Primary Breast Cancer,” Journal of Clinical Oncology, Vol. 24, No. 12, 2006, pp. 1839-1845.
doi:10.1200/JCO.2005.04.7019
|
[7]
|
S. Rathnagiriswaran, Y. W. Wan, J. Abraham, V. Castranova, Y. Qian and N. L. Guo, “A Population-Based Gene Signature is Predictive of Breast Cancer Survival and Chemoresponse,” International Journal of Oncology, Vol. 36, No. 3, 2010, pp. 607-616.
|
[8]
|
K. R. Hess, K. Anderson, W. F. Symmans, et al., “Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy with Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer,” Journal of Clinical Oncology, Vol. 24, No. 26, 2006, pp. 4236-4244.
|
[9]
|
R. Tibshirani, “Regression Shrinkage and Selection via the Lasso,” Journal of the Royal Statistical Society B, Vol. 58, No. 1, 1996, pp. 267-288.
|
[10]
|
G. C. Cawley and L. C. Talbot, “Gene Selection in Cancer Classification Using Sparse Logistic Regression with Bayesian Regularization,” Bioinformatics, Vol. 22, No. 19, 2006, pp. 2348-2355.
doi:10.1093/bioinformatics/btl386
|
[11]
|
S. Stylianou, R. B. Clarke, et al., “Activation of Notch Signaling in Human Breast Cancer,” Cancer Research, Vol. 66, No. 3, 2006, pp. 1517-1525.
doi:10.1158/0008-5472.CAN-05-3054
|
[12]
|
K. Brennan and A. M. C. Brown, “Is There a Role for Notch Signalling in Human Breast Cancer?” Breast Cancer Research, Vol. 5, No. 2, 2003, pp. 69-75.
doi:10.1186/bcr559
|
[13]
|
http://www.sabiosciences.com/rt_pcr_product/HTML/PAHS-059A.html
|
[14]
|
Y. H. Ou, P.-H. Chung, et al., “The Candidate Tumor Suppressor BTG3 Is a Transcriptional Target of P53 That Inhibits E2F1,” The EMBO Journal, Vol. 26, No. 17, 2007, pp. 3968-3980. doi:10.1038/sj.emboj.7601825
|
[15]
|
J. Starkova, J. Madzo, G. Cario, T. Kalina, A. Ford, M. Zaliova, O. Hrusak and J. Trka, “The Identification of (ETV6)/RUNX1-Regulated Genes in Lymphopoiesis Using Histone Deacetylase Inhibitors In ETV6/RUNX1- Positive Lymphoid Leukemic Cells,” Clinical Cancer Research, Vol. 13, No. 6, 2007, pp. 1726-1735.
doi:10.1158/1078-0432.CCR-06-2569
|
[16]
|
F. M. Mikhail, K. K. Sinha, Y. Saunthararajah and G. Nucifora, “Normal and Transforming Functions of RUNX1: A Perspective,” Journal of Cell Physiology, Vol. 207, No. 3, 2006, pp. 582-593.
doi:10.1002/jcp.20538
|
[17]
|
N. S. Goldstein, D. Decker, D. Severson, et al., “Molecular Classification System Identifies Invasive Breast Carcinoma Patients Who Are Most Likely and Those Who Are Least Likely to Achieve a Complete Pathologic Response after Neoadjuvant Chemotherapy,” Cancel, Vol. 110, No. 8, 2007, pp. 1687-1696.
doi:10.1002/cncr.22981
|